Novan

    OverviewSuggest Edit

    Novan is a clinical-stage biotechnology company focused on leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. It develops NITRICIL technology that allows the control of the level of nitric oxide storage, the rate of release, and the molecule size for targeted delivery.
    TypePrivate
    Founded2008
    HQNC, US
    Websitenovan.com
    Employee Ratings2.2

    Latest Updates

    Employees (est.) (Sept 2021)40
    Share Price (Sept 2021)$10.2(+4%)
    Cybersecurity ratingAMore

    Key People/Management at Novan

    Carri Geer

    Carri Geer

    SVP, Chief Technology Officer
    John M. Gay

    John M. Gay

    Chief Financial Officer
    W. Kent Geer

    W. Kent Geer

    Lead Independent Director
    Paula Brown Stafford

    Paula Brown Stafford

    President and Chief Executive Officer, Director
    Show more

    Novan Office Locations

    Novan has an office in Durham
    Durham, NC, US
    4020 Stirrup Creek Dr #110
    Show all (2)

    Novan Financials and Metrics

    Summary Metrics

    Founding Date

    2008

    Novan Cybersecurity Score

    Cybersecurity ratingPremium dataset

    A

    94/100

    SecurityScorecard logo

    Novan Online and Social Media Presence

    Embed Graph

    Novan News and Updates

    Novan Announces Strategic Priorities and Outlines Key Milestones

    – Company planning for three potential New Drug Application (NDA) filings in three years with the first submission expected in Q3 2022 for lead program SB206 in molluscum contagiosum –

    Novan Engages Syneos Health as Commercial Solutions Provider for SB206

    – Company targeting New Drug Application (NDA) for SB206 in Q3 2022, following recent clinically and statistically significant topline efficacy results from a pivotal Phase 3 B-SIMPLE4 trial in patients with molluscum contagiosum –

    Novan to Present at H.C. Wainwright 23rd Annual Global Investment Conference

    DURHAM, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will participate in a fireside chat during the September 13th – 15th H.C. Wainwright 23rd Annual Global…

    Novan to Host Corporate Update Conference Call and Webcast on September 9, 2021

    – Conference call with live audio webcast to be held on Thursday, September 9th at 8:30 a.m. ET –

    Novan Appoints Tomoko Maeda-Chubachi, MD, PhD, MBA as Chief Medical Officer

    – Dr. Maeda-Chubachi, who served as Novan’s Senior Vice President, Medical has played a key role in the design and execution of the Company’s development programs –

    Novan Reports Second Quarter 2021 Financial Results and Provides Corporate Update

    – Positive data across all three of the Company’s priority pipeline development programs, announced in Q2 2021, further validating the potential of its novel, proprietary NITRICIL™ technology –
    Show more

    Novan Blogs

    Novan Announces Closing of $40 Million Public Offering of Common Stock

    DURHAM, N.C., June 21, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company's previously announced underwritten public offering (the “Offering”) of 3,636,364 shares of common stock at a public offering price of $11.00 per share.

    Novan Announces Proposed Public Offering of Common Stock

    DURHAM, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company” or “Novan”) (NASDAQ: NOVN) today announced a proposed underwritten public offering of its common stock (the “Offering”). All shares to be sold in the Offering will be sold by Novan.

    Novan Announces 1-for-10 Reverse Stock Split

    Novan Announces 1-for-10 Reverse Stock Split Content Import Tue, 05/25/2021 - 08:01 Novan Announces 1-for-10 Reverse Stock Split May 25, 2021 at 8:01 AM EDT This release is a backfill from a News Wire Press Releases …

    Novan Reports First Quarter 2021 Financial Results and Provides Corporate Update

    – Topline efficacy results for ongoing Phase 3 study evaluating SB206 as a treatment for molluscum on track for targeted readout before the end of Q2 2021 – – Preclinical program underway evaluating SB019 with berdazimer sodium as a potential intranasal therapy for COVID-19, with results targeted

    Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology

    Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology Content Import Thu, 04/22/2021 - 09:01 Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology April 22, 2021 at 9:01 AM EDT Thi…

    Novan Bolsters Commercialization Expertise with Election of Steven D. Skolsky to Board of Directors

    – Recognized healthcare and life science industry leader with over 35 years of international product development, strategy and commercialization experience – MORRISVILLE, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the election of
    Show more

    Novan Frequently Asked Questions

    • When was Novan founded?

      Novan was founded in 2008.

    • Who are Novan key executives?

      Novan's key executives are Carri Geer, John M. Gay and W. Kent Geer.

    • How many employees does Novan have?

      Novan has 40 employees.

    • Who are Novan competitors?

      Competitors of Novan include Accellix, Arc Bio and Memo Therapeutics.

    • Where are Novan offices?

      Novan has an office in Durham.

    • How many offices does Novan have?

      Novan has 2 offices.